Related Experiment Video
Updated: Mar 25, 2026
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors
Mark R Woodford1, Diana Dunn2, Jonelle B Miller1
1Department of Urology, SUNY Upstate Medical University, Syracuse, New York, USA; Cancer Research Institute, SUNY Upstate Medical University, Syracuse, New York, USA.
Abstract:
Molecular chaperones are essential for guarding proteins that are indispensable for normal cellular functions. Heat shock protein 90 (Hsp90) is a vital molecular chaperone in eukaryotes that participates in stabilizing and activating approximately 200 target proteins, called "clients," many of which are involved in signal transduction pathways. Cancer cells however utilize Hsp90 to chaperone an array of mutated and overexpressed oncoproteins to protect them from misfolding and degradation. Therefore, Hsp90 is an attractive target in cancer therapy. Hsp90 chaperone function relies on ATP binding and hydrolysis, which in turn guides its carefully orchestrated conformational changes. This chaperone cycle is fine-tuned by another group of proteins called co-chaperones. They are able to accelerate or decelerate the cycle, allowing Hsp90 to chaperone different clients. Posttranslational modifications (PTMs) can also regulate the chaperone cycle at an epigenetic level thereby tailoring Hsp90 function to suit a specific cell type or environmental condition. Recent evidence suggests that inhibition of the enzymes that catalyze the PTM of Hsp90 can act synergistically with Hsp90 inhibitors, providing a novel therapeutic strategy to enhance the efficacy of Hsp90 inhibitors in cancer cells.
Insights
Heat shock protein 90 (Hsp90) chaperones oncoproteins in cancer cells. Inhibiting enzymes that modify Hsp90 alongside Hsp90 inhibitors offers a new strategy to improve cancer therapy effectiveness.
Area of Science:
- Molecular biology
- Cellular biology
- Biochemistry
Background:
- Molecular chaperones, like heat shock protein 90 (Hsp90), are crucial for maintaining normal cellular functions by stabilizing proteins.
- Cancer cells exploit Hsp90 to protect mutated and overexpressed oncoproteins from degradation, making Hsp90 a significant target in cancer therapy.
- Hsp90's function is regulated by ATP binding/hydrolysis, co-chaperones, and posttranslational modifications (PTMs), which fine-tune its activity for specific clients and conditions.
Purpose of the Study:
- To explore the role of Hsp90 in cancer and its regulation by co-chaperones and PTMs.
- To investigate the potential of targeting Hsp90 and its regulatory mechanisms for cancer treatment.
- To highlight novel therapeutic strategies involving Hsp90 inhibition.
Main Methods:
- Review of existing literature on Hsp90 function, regulation, and therapeutic targeting in cancer.
- Analysis of the interplay between Hsp90, its clients, co-chaperones, and PTMs.
- Examination of evidence for synergistic effects of combined Hsp90 inhibition and PTM enzyme inhibition.
Main Results:
- Hsp90 is essential for stabilizing oncoproteins in cancer cells.
- Co-chaperones and PTMs dynamically regulate the Hsp90 chaperone cycle.
- Inhibiting enzymes catalyzing Hsp90 PTMs shows synergistic effects with Hsp90 inhibitors in preclinical studies.
Conclusions:
- Hsp90 is a critical mediator of cancer cell survival and proliferation.
- Targeting Hsp90 alone or in combination with PTM-modulating agents represents a promising avenue for cancer therapy.
- Understanding the regulatory network of Hsp90 offers opportunities for developing more effective anti-cancer treatments.
More Related Videos
06:51Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
Published on: July 21, 2021
09:39Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology
Published on: March 31, 2022
Related Concept Videos
02:04Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...